Disease Area

drug pricing

Pharmaceutical drug pricing sits at the intersection of innovation incentives, payer sustainability, and patient access, driving intense policy and commercial debate globally. Reference pricing, indication-based pricing, and outcomes-based contracts are reshaping reimbursement frameworks in major markets. The Inflation Reduction Act provisions for Medicare negotiation in the US represent a landmark policy shift with industry-wide implications.

Drug Pricing
Vera Kidney Drug Wins Approval, Enhertu UK Deal Reached
Vera Therapeutics' atacicept secured FDA approval for IgA nephropathy, while a UK pricing deal will expand Enhertu access for breast cancer.
Get the full story
7 min read
Drug Pricing
Drug Approval Delays: 931 Days and Counting for European Patients
European patients wait an average of 931 days longer than US patients for access to new medicines, a systemic delay impacting clinical outcomes and public health.
Get the full story
9 min read
Drug Pricing
Big Pharma Employs UK Drug Pricing Tactics Across Europe
Pharmaceutical companies are replicating UK-style market access strategies to influence drug pricing negotiations in other European countries, impacting national healthcare budgets.
Get the full story
8 min read
Drug Pricing
Pharmacy Benefit Manager Reforms Address Systemic Issues
New legislative and regulatory reforms aim to rectify the 'fundamentally broken' pharmacy benefit manager (PBM) system, targeting opaque pricing and rebate practices.
Get the full story
7 min read

Loading articles...